Results 71 to 80 of about 28,682 (177)

Advances in reversible covalent kinase inhibitors

Medicinal Research Reviews, Volume 45, Issue 2, Page 629-653, March 2025.
Abstract Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects.
Zheng Zhao, Philip E. Bourne
wiley   +1 more source

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Biologics: Targets & Therapy, 2016
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous ...
Emole J, Talabi T, Pinilla-Ibarz J
doaj  

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients

Revista Brasileira de Hematologia e Hemoterapia, 2015
Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille, Ana Carolina de Almeida Bandeira, Aline Schiavoni Guarnieri da Silva   +2 more
doaj   +1 more source

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Clinical and Translational Science, Volume 18, Issue 3, March 2025.
ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis
Andrew G. Hadd, Angela Silvestro, Brittany Avin McKelvey, Jonathan Baden, Christina Bormann Chung, Ben Brown, Fernando Cruz‐Guilloty, James Godsey, Gregory Jones, Cheng‐Ho Jimmy Lin, Dorys Lopez Ramos, Daniel Norton, Melanie R. Palomares, Carol Pena, Thereasa Rich, Angel Rodriguez, Mark Stewart, Diana Merino Vega, Lauren C. Leiman   +18 more
wiley   +1 more source

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Revista Brasileira de Hematologia e Hemoterapia, 2012
BACKGROUND: Chronic myeloid leukemia is a neoplasm characterized by clonal expansion of hematopoietic progenitor cells resulting from the (9:22)(q34,11) translocation.
Maria Juracy Petrola, Alana Joselina Montenegro de Castro, Maria Helena da Silva Pitombeira, Maritza Cavalcante Barbosa, Acy Telles de Souza Quixadá, Fernando Barroso Duarte, Romelia Pinheiro Gonçalves   +6 more
doaj   +1 more source

Assessment of Treatment Outcome in Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors: Insight From a Resource Limited Setting

Cancer Medicine, Volume 14, Issue 3, February 2025.
ABSTRACT Background Chronic myeloid leukemia (CML) is a hematologic malignancy characterized by the translocation t(9;22)(q34;q11.2), which results in a constitutively active tyrosine kinase. The introduction of tyrosine kinase inhibitors (TKIs) has significantly altered the disease course for patients with BCR‐ABL1+ CML globally.
Wude Yewondwosen Awlachew, Abel Tenaw Tasamma, Firehiwot Abebe Mengistie, Zekarias Tadele Alemineh, Samuel Tesfaye Tefera   +4 more
wiley   +1 more source

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells

Cell Death Discovery
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation of circumventing signaling pathways and quiescence may limit BCR-ABLi efficacy.
Alvina I. Khamidullina, Margarita A. Yastrebova, Alexandra V. Bruter, Julia V. Nuzhina, Nadezhda E. Vorobyeva, Anastasia M. Khrustaleva, Ekaterina A. Varlamova, Alexander V. Tyakht, Iaroslav E. Abramenko, Ekaterina S. Ivanova, Maria A. Zamkova, Jing Li, Chang-Uk Lim, Mengqian Chen, Eugenia V. Broude, Igor B. Roninson, Alexander A. Shtil, Victor V. Tatarskiy   +17 more
doaj   +1 more source

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Revista Brasileira de Hematologia e Hemoterapia, 2011
Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors.
Ilana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, Paola Capelleti, Marcos de Lima, Jorge Cortes   +5 more
doaj   +1 more source

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Food Science &Nutrition, Volume 13, Issue 2, February 2025.
Illustrating the mechanism of Proteolysis Targeting Chimeras (PROTACs), development of ligands available for PROTACs, PROTACs targeting cancers, and its advantages. PROTACs offer a versatile strategy for personalized cancer treatment ABSTRACT Proteolysis Targeting Chimeras (PROTACs) have revolutionized cancer therapy by offering a selective and ...
Saooda Ibrahim, Muhammad Umer Khan, Iqra Khurram, Raima Rehman, Abdur Rauf, Zubair Ahmad, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Mohammed Mansour Quradha   +8 more
wiley   +1 more source

Pediatric chronic myeloid leukemia in myeloid blast crisis

Autopsy and Case Reports, 2023
Chronic myeloid leukemia (CML) accounts for 2-3% of childhood leukemias. About 5% of cases present in a blastic phase of CML which clinically and morphologically mimics more common acute leukemias of childhood.
Biswajit Dey, Anirban Dutta
doaj